Protocol Ledger

NCT07112196 · Phase II/III · RECRUITING

Visugromab in Cachexia International Trial

Interventional Phase II/III clinical trial protocol NCT07112196 sponsored by CatalYm in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-16 Enrollment: 518 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07112196
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)518 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07112196
Protocol FieldVerified Registry Value
NCT IdentifierNCT07112196
Consolidated Lead SponsorCatalYm
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment518 participants (ESTIMATED)
Registered Start Date2026-04-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07112196
Hospital Research SiteLocationSite Profile
Cleveland Clinic FloridaWeston, FLOpen Hospital Dossier ->
Augusta University Medical CenterAugusta, GAOpen Hospital Dossier ->
Cleveland ClinicCleveland, OHOpen Hospital Dossier ->
Fakultni nemocnice Hradec KraloveHradec Králové, CzechiaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI